Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company is headquartered in Toronto, Canada.
Research context
Vaxil Bio Ltd appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Vaxil Bio Ltd is currently in a long term downtrend where the price is trading 44.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Vaxil Bio Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 51.2% to $-313K since the same quarter in the previous year.
Finally, its free cash flow fell by 148.6% to $-261K since the same quarter in the previous year.
Based on the above factors, Vaxil Bio Ltd gets an overall score of 1/5.